AlphAIAlphAI — Financial news for AI agents
investing.comNOV 32 min read$WAT

Waters beats Q3 estimates, raises full-year guidance

Waters Corporation (NYSE:WAT) reported Q3 adjusted EPS of $4.10, beating estimates by $0.10, with revenue of $1.77B, up 121% YoY. The company raised full-year 2026 guidance, expecting adjusted EPS of $14.60-$14.70 and revenue of $6.48B-$6.50B. Q4 guidance was mixed. Organic revenue grew 9%, driven by strong divisional performance. The company also acquired MOBILion Systems, Inc.

Original reporting
investing.com
Published Nov 3, 2026, 11:21 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 3, 2026, 11:29 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefEarnings
Primary signal
$WAT
Bullish
high confidence
Mentioned
$WAT
Relevance
8/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$WATBullishHigh
01

Why it matters

The earnings beat and raised guidance suggest stronger demand for its products, potentially lifting the stock.

02

Market read

First‑report earnings and guidance raise make this a high‑value trading signal for WAT.

03

What to watch

Acquisition of MOBILion Systems may require integration capital and could dilute near‑term earnings.

Relevance 8/10Novelty 8/10Timing: pre‑market today

Background

Waters Corp (WAT) is a leading provider of analytical instruments and consumables for life‑science research and clinical labs.

Company-level read

Ticker impact

$WATBullishHigh confidence
Context

Waters reported Q3 earnings that beat estimates and raised full-year 2026 guidance above consensus.

Expected impact

likely upward as the market prices in the stronger guidance and earnings beat

Evidence & confidence

Both EPS and revenue beat expectations and guidance was raised, which typically drives buying interest.

Market effects

Sector

Strengthens outlook for analytical and biosciences equipment sector.

Regional

U.S. biotech and life‑science equipment stocks may see modest gains.

Global

Limited to investors tracking U.S. life‑science instrument makers.

Counterpoint

What could challenge this read

If the guidance upgrade is already priced in, the stock could face short‑term profit‑taking.

Key entities

  • company
    Waters Corporation

    Provider of analytical and biosciences instrumentation.

  • company
    MOBILion Systems, Inc.

    Acquired high‑resolution ion mobility separation technology firm.

Read at source← All news

StoryWaters Corp reports Q3 2026 earnings beat, raises 2026 guidance and announces MOBILion acquisition

Also covered by

5 outlets

Related articles

NOV 3
$WATHighAI 8/10

Waters Corporation (NYSE: WAT) Reports Third Quarter 2026 Financial Results

WATERS CORP /DE/ (WAT) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 For Immediate Release Contact: Caspar Tudor, Head of Investor Relations – (508) 482-3448 Waters Corporation (NYSE: WAT) Reports Third Quarter 2026 Financial Results Company to Provide Starting 2027 Growth Framework on Earnings Conference Call Third Quarter 2026 Highl

SEC EDGAR 8-K2 min
NOV 3
$WATHighAI 8/10

Waters Corp. Q3 Adjusted EPS Rises 21%; Raises Annual Outlook; Stock Up

Waters Corp. (WAT) reported Q3 net income fell to $81M ($0.82 EPS) due to costs, but adjusted EPS rose 21% to $4.10. Revenue hit $1.767B, with organic growth of 9%. The company raised its 2026 outlook, expecting organic revenue growth of 9.1% to 9.7% and adjusted EPS of $14.60 to $14.70. Shares rose 6% in pre-market trading.

rttnews.com2 min
NOV 3
$WATMed

Waters Acquires MOBILion Systems To Expand Proteomics Business

Waters Corp. (WAT) acquired MOBILion Systems to expand its proteomics business. The deal combines MOBILion's SLIM tech with Waters' Xevo MRT platform, aiming to enhance protein research. The LC-MS proteomics market is valued at $2B with high single-digit annual growth. Financial terms were not disclosed.

rttnews.com2 min
NOV 3
$WATHighAI 8/10

Waters earnings beat by $0.10, revenue topped estimates

Waters (WAT) reported Q3 EPS of $4.10, beating estimates by $0.10, with revenue at $1.77B, exceeding expectations. The company provided Q4 and FY 2026 guidance, with EPS and revenue estimates generally in line with or slightly above consensus. WAT's stock is up 12.47% over the last 3 months and 22.37% over the last 12 months.

investing.com2 min